Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Assets Average (2022 - 2025)

Entrada Therapeutics has reported Assets Average over the past 4 years, most recently at $395.1 million for Q4 2025.

  • Quarterly results put Assets Average at $395.1 million for Q4 2025, down 26.89% from a year ago — trailing twelve months through Dec 2025 was $395.1 million (down 26.89% YoY), and the annual figure for FY2025 was $451.8 million, down 9.22%.
  • Assets Average for Q4 2025 was $395.1 million at Entrada Therapeutics, down from $430.8 million in the prior quarter.
  • Over the last five years, Assets Average for TRDA hit a ceiling of $568.3 million in Q3 2024 and a floor of $263.3 million in Q4 2022.
  • Median Assets Average over the past 4 years was $477.1 million (2023), compared with a mean of $441.0 million.
  • Biggest five-year swings in Assets Average: surged 81.23% in 2023 and later dropped 26.89% in 2025.
  • Entrada Therapeutics' Assets Average stood at $263.3 million in 2022, then skyrocketed by 81.23% to $477.1 million in 2023, then grew by 13.28% to $540.5 million in 2024, then dropped by 26.89% to $395.1 million in 2025.
  • The last three reported values for Assets Average were $395.1 million (Q4 2025), $430.8 million (Q3 2025), and $467.6 million (Q2 2025) per Business Quant data.